Zimmer Biomet Holdings, Inc. $ZBH Stock Holdings Raised by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 24.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,237,109 shares of the medical equipment provider’s stock after acquiring an additional 245,599 shares during the period. Thrivent Financial for Lutherans’ holdings in Zimmer Biomet were worth $111,241,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Rakuten Investment Management Inc. bought a new stake in shares of Zimmer Biomet in the 3rd quarter worth about $37,307,000. Sector Gamma AS increased its position in shares of Zimmer Biomet by 28.0% in the 3rd quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock worth $11,178,000 after purchasing an additional 24,847 shares during the last quarter. Border to Coast Pensions Partnership Ltd grew its position in shares of Zimmer Biomet by 6.5% during the 3rd quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock valued at $35,506,000 after buying an additional 22,104 shares during the last quarter. National Pension Service grew its position in shares of Zimmer Biomet by 4.5% during the 3rd quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock valued at $38,757,000 after buying an additional 16,928 shares during the last quarter. Finally, AMG National Trust Bank grew its position in shares of Zimmer Biomet by 29.1% during the 3rd quarter. AMG National Trust Bank now owns 50,359 shares of the medical equipment provider’s stock valued at $4,960,000 after buying an additional 11,339 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 0.0%

Zimmer Biomet stock opened at $82.71 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The firm has a 50-day moving average price of $89.84 and a two-hundred day moving average price of $91.57. The firm has a market capitalization of $16.00 billion, a price-to-earnings ratio of 21.48, a PEG ratio of 1.91 and a beta of 0.48. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. The firm had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. Zimmer Biomet’s revenue was up 9.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.47 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend was Tuesday, March 31st. Zimmer Biomet’s payout ratio is presently 24.94%.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of recent research reports. Wall Street Zen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Citizens Jmp lowered their price objective on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research report on Wednesday, April 29th. Leerink Partners initiated coverage on shares of Zimmer Biomet in a research report on Monday, April 13th. They set a “hold” rating and a $101.00 price objective for the company. Robert W. Baird set a $92.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Finally, Barclays lowered their price objective on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $102.80.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the business’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. The trade was a 20.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.28% of the stock is owned by insiders.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.